aBLA Filing Intelligence & Biosimilar Opportunity

Aduhelm

Aducanumab-Avwa

Antialzheimer

Injection Injectable

Approval Date

06-Jul-21

Data Exclusivity Expiry

06-Jul-25

Market Exclusivity Expiry

06-Jul-33

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Aducanumab-Avwa

Innovator

BIOGEN INC

Dosage Form

Injection Injectable

Strength

170 mg/1.7 mL (100 mg/mL), 300 mg/3 mL (100 mg/mL)

Therapeutic Category

Antialzheimer

Usage

To treat Alzheimer’s disease

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.